Bangladesh

Total population (2018) 166,724,957
Birth cohort (2018) 3,073,697
Surviving Infants (surviving to 1 year per year, 2018) 2,997,362
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 31/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 38/1000
World Bank Index, IDA (2015) 3.31
Gross Nation Income (per capita US$, 2015) 1,190
No. of districts/territories (2017) 64


Cash Support (CASHSUPP) | $333,500 | $358,500 | $333,500 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Health system strengthening (HSS 1) | $13,671,500 | $13,671,500 | $13,671,500 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Health system strengthening (HSS 2) | $37,922,731 | $37,922,731 | $33,738,731 | 89% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HepB mono (NVs) | $20,224,465 | $20,224,465 | $20,224,465 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HPV Demo (NVs) | $715,990 | $715,990 | $716,562 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Immunisation services support (ISS) | $23,340,200 | $23,340,200 | $23,340,200 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Injection Safety Devices (NVs) | $4,883,460 | $6,608,960 | $2,014,410 | 41% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Injection safety support (INS) | $6,144,414 | $6,144,414 | $6,144,414 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IPV (NVs) | $20,930,409 | $20,930,409 | $20,930,409 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IPV Catch-up RI (NVs) | $1,748,500 | $1,748,500 | $1,051,843 | 60% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Measles (NVs) | $9,702,862 | $9,702,862 | $9,740,021 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Measles-Rubella (NVs) | $36,040,812 | $36,040,812 | $36,046,414 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
MR - Operational costs (OPC) | $33,586,500 | $33,586,500 | $33,586,500 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
MR 1st and 2nd dose (NVs) | $494,500 | $494,500 | $431,934 | 87% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
MR-Catch-up campaign (NVs) | $189,500 | $189,500 | $186,371 | 98% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operational costs (OPC) | $451,257 | $451,257 | $451,257 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Penta (NVs) | $253,092,587 | $273,663,587 | $258,162,446 | 102% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Penta - campaign (NVs) | $153,000 | $153,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pneumo (NVs) | $212,505,412 | $266,495,412 | $196,556,773 | 92% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Switch Grant (PSG) | $8,314,000 | $8,314,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rotavirus (NVs) | N/A | N/A |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vaccine Introduction Grant (VIG) | $8,314,000 | $8,314,000 | $8,314,000 | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total | $684,705,314 | $761,036,814 | $659,812,220 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding.
DTP3 - WHO/UNICEF estimates (2017)  
Grade of confidence: N/A

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTP3 - Official country estimates (2017)</td>
<td>90%</td>
</tr>
<tr>
<td>M:F sex ratio at birth (2018)</td>
<td>1.05</td>
</tr>
<tr>
<td>Household survey: DTP3 coverage for male (2013)</td>
<td>90.40%</td>
</tr>
<tr>
<td>Household survey: DTP3 coverage for female (2013)</td>
<td>92.30%</td>
</tr>
<tr>
<td>Household survey: Last DTP3 survey (2013)</td>
<td>91%</td>
</tr>
<tr>
<td>% districts achieving &gt; 80% DTP3 coverage (2017)</td>
<td>100%</td>
</tr>
<tr>
<td>% districts achieving &lt; 50% DTP3 coverage (2017)</td>
<td>0%</td>
</tr>
<tr>
<td>MCV WHO/UNICEF estimates (2017)</td>
<td>94%</td>
</tr>
</tbody>
</table>

Disclaimer: the boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of Gavi, the Vaccine Alliance concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.